- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
GSK269962A HCl
別名: GSK269962B, GSK269962
GSK269962A HCl是選擇性的ROCK(Rho-associated protein kinase)抑制劑，對ROCK1和ROCK2的IC50分別為1.6 nM和4 nM。
GSK269962A HCl Chemical Structure
CAS: 2095432-71-4
產(chǎn)品質(zhì)控
批次：
純度：
99.59%
99.59
GSK269962A HCl相關(guān)產(chǎn)品
| 相關(guān)靶點 | ROCK1 ROCK2 | 點擊展開 |
|---|---|---|
| 相關(guān)產(chǎn)品 | Y-27632 2HCl Y-27632 Fasudil HCl Thiazovivin GSK429286A RKI-1447 Ripasudil hydrochloride dihydrate Y-39983 Dihydrochloride Hydroxyfasudil HCl | 點擊展開 |
| 相關(guān)化合物庫 | 激酶抑制劑庫 PI3K/Akt 抑制劑庫 MAPK抑制劑庫 DNA損傷/ DNA修復(fù)化合物庫 細胞周期化合物庫 | 點擊展開 |
相關(guān)信號通路圖
細胞實驗數(shù)據(jù)示例
| 細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
|---|---|---|---|---|---|
| NCI-H1581 | Growth inhibition assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50=18.8477 μM | SANGER | ||
| NCI-H1694 | Growth inhibition assay | Inhibition of human NCI-H1694 cell growth in a cell viability assay, IC50=24.8749 μM | SANGER | ||
| NCI-H1963 | Growth inhibition assay | Inhibition of human NCI-H1963 cell growth in a cell viability assay, IC50=1.27839 μM | SANGER | ||
| NCI-H2081 | Growth inhibition assay | Inhibition of human NCI-H2081 cell growth in a cell viability assay, IC50=34.6044 μM | SANGER | ||
| NCI-H209 | Growth inhibition assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50=22.6272 μM | SANGER | ||
| NCI-H2107 | Growth inhibition assay | Inhibition of human NCI-H2107 cell growth in a cell viability assay, IC50=25.6561 μM | SANGER | ||
| NCI-H2126 | Growth inhibition assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50=6.50426 μM | SANGER | ||
| NCI-H2171 | Growth inhibition assay | Inhibition of human NCI-H2171 cell growth in a cell viability assay, IC50=0.95937 μM | SANGER | ||
| NCI-H2227 | Growth inhibition assay | Inhibition of human NCI-H2227 cell growth in a cell viability assay, IC50=7.88616 μM | SANGER | ||
| NCI-H524 | Growth inhibition assay | Inhibition of human NCI-H524 cell growth in a cell viability assay, IC50=22.8763 μM | SANGER | ||
| NCI-H526 | Growth inhibition assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50=18.5431 μM | SANGER | ||
| NCI-H720 | Growth inhibition assay | Inhibition of human NCI-H720 cell growth in a cell viability assay, IC50=2.45161 μM | SANGER | ||
| NMC-G1 | Growth inhibition assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50=15.0578 μM | SANGER | ||
| NOS-1 cell | Growth inhibition assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=5.82294 μM | SANGER | ||
| OCI-AML2 cell | Growth inhibition assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50=10.9496 μM | SANGER | ||
| OCUB-M cell | Growth inhibition assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50=17.201 μM | SANGER | ||
| ONS-76 cell | Growth inhibition assay | Inhibition of human ONS-76 cell growth in a cell viability assay, IC50=13.9191 μM | SANGER | ||
| OS-RC-2 cell | Growth inhibition assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50=46.195 μM | SANGER | ||
| OVCAR-4 cell | Growth inhibition assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50=8.71808 μM | SANGER | ||
| P30-OHK cell | Growth inhibition assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50=7.62877 μM | SANGER | ||
| P30-OHK cell | Growth inhibition assay | Inhibition of human PF-382 cell growth in a cell viability assay, IC50=7.04954 μM | SANGER | ||
| PSN1 cell | Growth inhibition assay | Inhibition of human PSN1 cell growth in a cell viability assay, IC50=6.22126 μM | SANGER | ||
| QIMR-WIL cell | Growth inhibition assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=0.49004 μM | SANGER | ||
| RCC10RGB cell | Growth inhibition assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50=18.9036 μM | SANGER | ||
| RKO cell | Growth inhibition assay | Inhibition of human RKO cell growth in a cell viability assay, IC50=10.5662 μM | SANGER | ||
| RL95-2 cell | Growth inhibition assay | Inhibition of human RL95-2 cell growth in a cell viability assay, IC50=10.67 μM | SANGER | ||
| RPMI-6666 cell | Growth inhibition assay | Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50=18.5236 μM | SANGER | ||
| RPMI-8402 cell | Growth inhibition assay | Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50=4.5856 μM | SANGER | ||
| RXF393 cell | Growth inhibition assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50=0.393 μM | SANGER | ||
| Ramos-2G6-4C10 cell | Growth inhibition assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50=1.357 μM | SANGER | ||
| SCLC-21H cell | Growth inhibition assay | Inhibition of human SCLC-21H cell growth in a cell viability assay, IC50=7.61149 μM | SANGER | ||
| SF126 cell | Growth inhibition assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50=11.8321μM | SANGER | ||
| SF268 cell | Growth inhibition assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50=6.23183 μM | SANGER | ||
| SF539 cell | Growth inhibition assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50=1.28661 μM | SANGER | ||
| SH-4 cell | Growth inhibition assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50=5.75508 μM | SANGER | ||
| SIG-M5 cell | Growth inhibition assay | Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50=11.7259 μM | SANGER | ||
| SJSA-1 cell | Growth inhibition assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50=1.04526 μM | SANGER | ||
| SK-LMS-1 cell | Growth inhibition assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50=32.5965 μM | SANGER | ||
| SK-MM-2 cell | Growth inhibition assay | Inhibition of human SK-MM-2 cell growth in a cell viability assay, IC50=42.3405 μM | SANGER | ||
| SK-N-DZ cell | Growth inhibition assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50=9.48314 μM | SANGER | ||
| SK-NEP-1 cell | Growth inhibition assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50=17.5456 μM | SANGER | ||
| SK-PN-DW cell | Growth inhibition assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50=24.9736 μM | SANGER | ||
| SNB75 cell | Growth inhibition assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50=8.07737 μM | SANGER | ||
| SR cell | Growth inhibition assay | Inhibition of human SR cell growth in a cell viability assay, IC50=0.000137 μM | SANGER | ||
| SU-DHL-1 cell | Growth inhibition assay | Inhibition of human SU-DHL-1 cell growth in a cell viability assay, IC50=12.7336 μM | SANGER | ||
| SW684 cell | Growth inhibition assay | Inhibition of human SW684 cell growth in a cell viability assay, IC50=39.011 μM | SANGER | ||
| SW872 cell | Growth inhibition assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50=0.88656 μM | SANGER | ||
| SW962 cell | Growth inhibition assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50=12.7521 μM | SANGER | ||
| 697 cell | Growth inhibition assay | Inhibition of human 697 cell growth in a cell viability assay, IC50=0.2991 μM | SANGER | ||
| 8-MG-BA cell | Growth inhibition assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50=23.0793 μM | SANGER | ||
| A101D cell | Growth inhibition assay | Inhibition of human A101D cell growth in a cell viability assay, IC50=1.87034 μM | SANGER | ||
| ACN cell | Growth inhibition assay | Inhibition of human ACN cell growth in a cell viability assay, IC50=21.4387 μM | SANGER | ||
| AM-38 cell | Growth inhibition assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50=7.26327 μM | SANGER | ||
| ATN-1 cell | Growth inhibition assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50=24.7555 μM | SANGER | ||
| BB30-HNC cell | Growth inhibition assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50=22.2532 μM | SANGER | ||
| BB49-HNC cell | Growth inhibition assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50=0.00789 μM | SANGER | ||
| human BC-1 cell | Growth inhibition assay | Inhibition of human BC-1 cell growth in a cell viability assay, IC50=3.97107 μM | SANGER | ||
| BE-13 cell | Growth inhibition assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50=0.14081μM | SANGER | ||
| BL-70 cell | Growth inhibition assay | Inhibition of human BL-70 cell growth in a cell viability assay, IC50=3.40703 μM | SANGER | ||
| BV-173 cell | Growth inhibition assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50=18.8859 μM | SANGER | ||
| Becker cell | Growth inhibition assay | Inhibition of human Becker cell growth in a cell viability assay, IC50=13.9545 μM | SANGER | ||
| CAL-148 cell | Growth inhibition assay | Inhibition of human CAL-148 cell growth in a cell viability assay, IC50=35.6557 μM | SANGER | ||
| TE-10 cell | Growth inhibition assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50=22.8423 μM | SANGER | ||
| TE-12 cell | Growth inhibition assay | Inhibition of human TE-12 cell growth in a cell viability assay, IC50=32.4114 μM | SANGER | ||
| TE-8 cell | Growth inhibition assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50=11.6089 μM | SANGER | ||
| TE-9 cell | Growth inhibition assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50=36.6381 μM | SANGER | ||
| TGW cell | Growth inhibition assay | Inhibition of human TGW cell growth in a cell viability assay, IC50=23.3577 μM | SANGER | ||
| UACC-257 cell | Growth inhibition assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50=8.70625 μM | SANGER | ||
| WSU-NHL cell | Growth inhibition assay | Inhibition of human WSU-NHL cell growth in a cell viability assay, IC50=27.1907 μM | SANGER | ||
| no-10 cell | Growth inhibition assay | Inhibition of human no-10 cell growth in a cell viability assay, IC50=0.66846 μM | SANGER | ||
| no-11 cell | Growth inhibition assay | Inhibition of human no-11 cell growth in a cell viability assay, IC50=47.0263 μM | SANGER | ||
| CAS-1 cell | Growth inhibition assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50=0.847 μM | SANGER | ||
| CCRF-CEM cell | Growth inhibition assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50=8.65392 μM | SANGER | ||
| CMK cell | Growth inhibition assay | Inhibition of human CMK cell growth in a cell viability assay, IC50=1.01323 μM | SANGER | ||
| COLO-829 cell | Growth inhibition assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50=3.24226 μM | SANGER | ||
| COR-L279 cell | Growth inhibition assay | Inhibition of human COR-L279 cell growth in a cell viability assay, IC50=2.0738 μM | SANGER | ||
| CP66-MEL cell | Growth inhibition assay | Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50=36.5497 μM | SANGER | ||
| CRO-AP2 cell | Growth inhibition assay | Inhibition of human CRO-AP2 cell growth in a cell viability assay, IC50=2.36088 μM | SANGER | ||
| CTV-1 cell | Growth inhibition assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50=23.9145 μM | SANGER | ||
| Calu-6 cell | Growth inhibition assay | Inhibition of human Calu-6 cell growth in a cell viability assay, IC50=47.586 μM | SANGER | ||
| D-247MG cell | Growth inhibition assay | Inhibition of human D-247MG cell growth in a cell viability assay, IC50=0.62814 μM | SANGER | ||
| D-263MG cell | Growth inhibition assay | Inhibition of human D-263MG cell growth in a cell viability assay, IC50=0.08509 μM | SANGER | ||
| D-336MG cell | Growth inhibition assay | Inhibition of human D-336MG cell growth in a cell viability assay, IC50=0.62854 μM | SANGER | ||
| D-392MG cell | Growth inhibition assay | Inhibition of human D-392MG cell growth in a cell viability assay, IC50=1.43039 μM | SANGER | ||
| D-502MG cell | Growth inhibition assay | Inhibition of human D-502MG cell growth in a cell viability assay, IC50=8.53492 μM | SANGER | ||
| D-542MG cell | Growth inhibition assay | Inhibition of human D-542MG cell growth in a cell viability assay, IC50=12.3152 μM | SANGER | ||
| DB cell | Growth inhibition assay | Inhibition of human DB cell growth in a cell viability assay, IC50=47.1417 μM | SANGER | ||
| DEL cell | Growth inhibition assay | Inhibition of human DEL cell growth in a cell viability assay, IC50=7.01898 μM | SANGER | ||
| DMS-114 cell | Growth inhibition assay | Inhibition of human DMS-114 cell growth in a cell viability assay, IC50=49.8468 μM | SANGER | ||
| DMS-153 cell | Growth inhibition assay | Inhibition of human DMS-153 cell growth in a cell viability assay, IC50=42.9923 μM | SANGER | ||
| DOHH-2 cell | Growth inhibition assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50=4.22764 μM | SANGER | ||
| DSH1 cell | Growth inhibition assay | Inhibition of human DSH1 cell growth in a cell viability assay, IC50=8.43623 μM | SANGER | ||
| Daudi cell | Growth inhibition assay | Inhibition of human Daudi cell growth in a cell viability assay, IC50=2.09802 μM | SANGER | ||
| EC-GI-10 cell | Growth inhibition assay | Inhibition of human EC-GI-10 cell growth in a cell viability assay, IC50=44.2589 μM | SANGER | ||
| ECC4 cell | Growth inhibition assay | Inhibition of human ECC4 cell growth in a cell viability assay, IC50=32.1896 μM | SANGER | ||
| EM-2 cell | Growth inhibition assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50=2.45594 μM | SANGER | ||
| ES1 cell | Growth inhibition assay | Inhibition of human ES1 cell growth in a cell viability assay, IC50=5.54087 μM | SANGER | ||
| ES3 cell | Growth inhibition assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50=42.4729 μM | SANGER | ||
| ES4 cell | Growth inhibition assay | Inhibition of human ES4 cell growth in a cell viability assay, IC50=35.195 μM | SANGER | ||
| ES6 cell | Growth inhibition assay | Inhibition of human ES6 cell growth in a cell viability assay, IC50=0.24733 μM | SANGER | ||
| ES7 cell | Growth inhibition assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50=5.23124 μM | SANGER | ||
| ES8 cell | Growth inhibition assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50=0.81924 μM | SANGER | ||
| EW-18 cell | Growth inhibition assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50=13.6759 μM | SANGER | ||
| EW-22 cell | Growth inhibition assay | Inhibition of human EW-22 cell growth in a cell viability assay, IC50=47.7947 μM | SANGER | ||
| GCIY cell | Growth inhibition assay | Inhibition of human GCIY cell growth in a cell viability assay, IC50=9.80389 μM | SANGER | ||
| GDM-1 cell | Growth inhibition assay | Inhibition of human GDM-1 cell growth in a cell viability assay, IC50=8.39196 μM | SANGER | ||
| GI-1 cell | Growth inhibition assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50=0.00523 μM | SANGER | ||
| GI-ME-N cell | Growth inhibition assay | Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50=0.04951 μM | SANGER | ||
| GR-ST cell | Growth inhibition assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50=13.7902 μM | SANGER | ||
| GT3TKB cell | Growth inhibition assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50=1.60389 μM | SANGER | ||
| HAL-01 cell | Growth inhibition assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50=6.69712 μM | SANGER | ||
| HCC1599 cell | Growth inhibition assay | Inhibition of human HCC1599 cell growth in a cell viability assay, IC50=37.6011 μM | SANGER | ||
| HCC2218 cell | Growth inhibition assay | Inhibition of human HCC2218 cell growth in a cell viability assay, IC50=13.3834 μM | SANGER | ||
| HD-MY-Z cell | Growth inhibition assay | Inhibition of human HD-MY-Z cell growth in a cell viability assay, IC50=25.2146 μM | SANGER | ||
| HL-60 cell | Growth inhibition assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50=12.2114 μM | SANGER | ||
| HOP-62 cell | Growth inhibition assay | Inhibition of human HOP-62 cell growth in a cell viability assay, IC50=23.9527 μM | SANGER | ||
| HT cell | Growth inhibition assay | Inhibition of human HT cell growth in a cell viability assay, IC50=4.44321 μM | SANGER | ||
| HT-144 cell | Growth inhibition assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50=4.90686 μM | SANGER | ||
| HUTU-80 cell | Growth inhibition assay | Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50=3.78986 μM | SANGER | ||
| IST-MEL1 cell | Growth inhibition assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50=32.9086 μM | SANGER | ||
| IST-SL1 cell | Growth inhibition assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50=2.17079 μM | SANGER | ||
| IST-SL2 cell | Growth inhibition assay | Inhibition of human IST-SL2 cell growth in a cell viability assay, IC50=3.26608 μM | SANGER | ||
| K052 cell | Growth inhibition assay | Inhibition of human K052 cell growth in a cell viability assay, IC50=0.75301 μM | SANGER | ||
| K5 cell | Growth inhibition assay | Inhibition of human K5 cell growth in a cell viability assay, IC50=33.5915 μM | SANGER | ||
| KALS-1 cell | Growth inhibition assay | Inhibition of human KALS-1 cell growth in a cell viability assay, IC50=29.3969 μM | SANGER | ||
| KARPAS-422 cell | Growth inhibition assay | Inhibition of human KARPAS-422 cell growth in a cell viability assay, IC50=42.9142 μM | SANGER | ||
| KARPAS-45 cell | Growth inhibition assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50=4.11247 μM | SANGER | ||
| KE-37 cell | Growth inhibition assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50=9.835 μM | SANGER | ||
| KG-1 cell | Growth inhibition assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50=23.9757 μM | SANGER | ||
| KGN cell | Growth inhibition assay | Inhibition of human KGN cell growth in a cell viability assay, IC50=0.56742 μM | SANGER | ||
| KM12 cell | Growth inhibition assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50=3.52964 μM | SANGER | ||
| KMOE-2 cell | Growth inhibition assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50=30.4549 μM | SANGER | ||
| KNS-42 cell | Growth inhibition assay | Inhibition of human KNS-42 cell growth in a cell viability assay, IC50=8.81915 μM | SANGER | ||
| KNS-81-FD cell | Growth inhibition assay | Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50=37.426 μM | SANGER | ||
| KS-1 cell | Growth inhibition assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50=0.0046 μM | SANGER | ||
| KU812 cell | Growth inhibition assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50=23.484 μM | SANGER | ||
| L-540 cell | Growth inhibition assay | Inhibition of human L-540 cell growth in a cell viability assay, IC50=20.7445 μM | SANGER | ||
| LAMA-84 cell | Growth inhibition assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50=13.6742 μM | SANGER | ||
| LB1047-RCC cell | Growth inhibition assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=28.3883 μM | SANGER | ||
| LB2241-RCC cell | Growth inhibition assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50=10.5536 μM | SANGER | ||
| LB2518-MEL cell | Growth inhibition assay | Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50=1.71496μM | SANGER | ||
| LB831-BLC cell | Growth inhibition assay | Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50=11.1726 μM | SANGER | ||
| LB996-RCC cell | Growth inhibition assay | Inhibition of human LB996-RCC cell growth in a cell viability assay, IC50=12.7431 μM | SANGER | ||
| LC4-1 cell | Growth inhibition assay | Inhibition of human LC4-1 cell growth in a cell viability assay, IC50=32.8341 μM | SANGER | ||
| LOUCY cell | Growth inhibition assay | Inhibition of human LOUCY cell growth in a cell viability assay, IC50=1.15276 μM | SANGER | ||
| LOXIMVI cell | Growth inhibition assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50=30.2122 μM | SANGER | ||
| LS-123 cell | Growth inhibition assay | Inhibition of human LS-123 cell growth in a cell viability assay, IC50=39.2258 μM | SANGER | ||
| LU-134-A cell | Growth inhibition assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50=7.14068 μM | SANGER | ||
| LU-139 cell | Growth inhibition assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50=22.218 μM | SANGER | ||
| LXF-289 cell | Growth inhibition assay | Inhibition of human LXF-289 cell growth in a cell viability assay, IC50=17.4351μM | SANGER | ||
| MC116 cell | Growth inhibition assay | Inhibition of human MC116 cell growth in a cell viability assay, IC50=45.0841 μM | SANGER | ||
| MDA-MB-134-VI cell | Growth inhibition assay | Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay, IC50=39.2486 μM | SANGER | ||
| MFH-ino cell | Growth inhibition assay | Inhibition of human MFH-ino cell growth in a cell viability assay, IC50=0.64383 μM | SANGER | ||
| MHH-NB-11 cell | Growth inhibition assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50=0.0669 μM | SANGER | ||
| ML-2 cell | Growth inhibition assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50=3.40304 μM | SANGER | ||
| MOLT-13 cell | Growth inhibition assay | Inhibition of human MOLT-13 cell growth in a cell viability assay, IC50=4.43653 μM | SANGER | ||
| MOLT-16 cell | Growth inhibition assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50=4.11163 μM | SANGER | ||
| MOLT-4 cell | Growth inhibition assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50=14.4124 μM | SANGER | ||
| MPP-89 cell | Growth inhibition assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50=1.25922 μM | SANGER | ||
| MRK-nu-1 cell | Growth inhibition assay | Inhibition of human MRK-nu-1 cell growth in a cell viability assay, IC50=0.57572 μM | SANGER | ||
| MSTO-211H cell | Growth inhibition assay | Inhibition of human MSTO-211H cell growth in a cell viability assay, IC50=12.869 μM | SANGER | ||
| MV-4-11 cell | Growth inhibition assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=0.13915 μM | SANGER | ||
| NALM-6 cell | Growth inhibition assay | Inhibition of human NALM-6 cell growth in a cell viability assay, IC50=1.56109 μM | SANGER | ||
| NB1 cell | Growth inhibition assay | Inhibition of human NB1 cell growth in a cell viability assay, IC50=3.84369 μM | SANGER | ||
| NB10 cell | Growth inhibition assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50=0.13915 μM | SANGER | ||
| NB12 cell | Growth inhibition assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50=16.5656 μM | SANGER | ||
| NB13 cell | Growth inhibition assay | Inhibition of human NB13 cell growth in a cell viability assay, IC50=2.31278 μM | SANGER | ||
| NB17 cell | Growth inhibition assay | Inhibition of human NB17 cell growth in a cell viability assay, IC50=3.58051 μM | SANGER | ||
| NB6 cell | Growth inhibition assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50=0.59114 μM | SANGER | ||
| NCCIT cell | Growth inhibition assay | Inhibition of human NCCIT cell growth in a cell viability assay, IC50=41.8453 μM | SANGER | ||
| NCI-H1155 cell | Growth inhibition assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50=14.3408 μM | SANGER | ||
| NCI-H1304 cell | Growth inhibition assay | Inhibition of human NCI-H1304 cell growth in a cell viability assay, IC50=11.8982 μM | SANGER | ||
| NCI-H1355 cell | Growth inhibition assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50=4.9411 μM | SANGER | ||
| NCI-H1395 cell | Growth inhibition assay | Inhibition of human NCI-H1395 cell growth in a cell viability assay, IC50=22.8795 μM | SANGER | ||
| NCI-H1417 cell | Growth inhibition assay | Inhibition of human NCI-H1417 cell growth in a cell viability assay, IC50=5.67522 μM | SANGER | ||
| NCI-H1436 cell | Growth inhibition assay | Inhibition of human NCI-H1436 cell growth in a cell viability assay, IC50=3.84101 μM | SANGER | ||
| NTERA-S-cl-D1 cell | Growth inhibition assay | Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50=12.8935 μM | SANGER | ||
| JiyoyeP-2003 cell | Growth inhibition assay | Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay, IC50=36.6284 μM | SANGER | ||
| 點擊查看更多細胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | GSK269962A HCl是選擇性的ROCK(Rho-associated protein kinase)抑制劑，對ROCK1和ROCK2的IC50分別為1.6 nM和4 nM。 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 靶點 |
|
| 體外研究(In Vitro) | ||||
| 體外研究活性 | GSK269962A在人類平滑肌中，完全阻斷血管緊張肽Ⅱ誘導(dǎo)的肌動蛋白張力絲的形成。這一抑制現(xiàn)象始于約1 μM GSK269962A。GSK269962A在預(yù)束緊的大鼠動脈（組織浴/組織培養(yǎng)）中誘導(dǎo)血管舒張，IC50為35 nM。GSK269962A所誘導(dǎo)的舒張是可逆的。GSK269962A在巨噬細胞中抑制IL-6 mRNA的轉(zhuǎn)錄、減少LPS誘導(dǎo)的IL-6和TNF-α蛋白的產(chǎn)生[1]。 | |||
|---|---|---|---|---|
| 細胞實驗 | 細胞系 | 平滑肌細胞 | ||
| 濃度 | 3 μM | |||
| 孵育時間 | 150 min | |||
| 方法 | 對人類平滑肌細胞進行血清饑餓處理（細胞于蓋玻片上生長，達到50%融合時，血清饑餓處理過夜），用AngⅡ（100 nM）對其進行刺激2小時。在刺激前30分鐘，加入ROCK抑制劑（3 μM SB-772077-B或GSK269962A），刺激后將細胞進行固定，用鬼筆環(huán)肽對肌動蛋白進行染色。 | |||
| 體內(nèi)研究(In Vivo) | ||
| 體內(nèi)研究活性 | 自發(fā)性高血壓大鼠口服GSK269962A將降低體循環(huán)血壓，血壓的減少非常迅速并顯著。在口服給藥后約2小時，其降血壓作用達到峰值。血壓的減少伴隨著急性、劑量依賴性的心率增加，這可能是壓力反射機制的激活[1]。用10 mg/kg的GSK 269962抑制ROCK在大鼠內(nèi)能依次地引起排尿量、排尿后殘余尿、容量閾值、泌尿效率、ICI(intercontraction interval)、膀胱順應(yīng)性、VTNVC的升高，而對心率、收縮壓、平均血壓、舒張壓沒有影響[2]。 | |
|---|---|---|
| 動物實驗 | Animal Models | Wistar雌性大鼠 |
| Dosages | 5 或 10 mg/kg | |
| Administration | 動脈注射 | |
化學(xué)信息&溶解度
| 分子量 | 607.06 | 分子式 | C29H30N8O5.HCl |
| CAS號 | 2095432-71-4 | SDF | Download GSK269962A HCl SDF |
| Smiles | CCN1C2=CC(=NC=C2N=C1C3=NON=C3N)OC4=CC=CC(=C4)NC(=O)C5=CC=C(C=C5)OCCN6CCOCC6.Cl | ||
| 儲存條件(自收到貨起) | |||
|
體外溶解度 |
DMSO : 100 mg/mL ( (164.72 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Ethanol : 28 mg/mL (46.12 mM) Water : Insoluble |
摩爾濃度計算器 |
|
體內(nèi)溶解度 現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 | ||||
實驗計算
動物體內(nèi)配方計算器（澄清溶液）
第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項
Tags: buy GSK269962A HCl | GSK269962A HCl supplier | purchase GSK269962A HCl | GSK269962A HCl cost | GSK269962A HCl manufacturer | order GSK269962A HCl | GSK269962A HCl distributor
